-Reuters
UBS Maintains Buy on CareMax, Lowers Price Target to $6
UBS analyst Andrew Mok maintains CareMax (NASDAQ:CMAX) with a Buy and lowers the price target from $10 to $6.
Related Posts
Senate Majority Leader Schumer Tweets ‘We must end the federal prohibition on marijuana while ensuring restorative justice for those harmed by the War on Drugs. I’m working with @SenBooker and @RonWyden on comprehensive marijuana reform legislation.’
https://twitter.com/SenSchumer/status/1413223092919361536
Wells Fargo Maintains Overweight on Medtronic, Raises Price Target to $151
Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $140 to $151.
Bristol Myers Squibb Receives Approval For Abecma, The First CAR T Therapy Approved For The Treatment Of Multiple Myeloma In Japan
https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Receives-Approval-for-Abecma-idecabtagene-vicleucel-the-First-CAR-T-Therapy-Approved-for-the-Treatment-of-Multiple-Myeloma-in-Japan/default.aspx